文献速递糖尿病

司美格鲁肽对有症状外周动脉疾病患者的获益:基于基线2型糖尿病特征的STRIDE随机安慰剂对照双盲试验分析

Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.
PubMed 文献 · Diabetes Care · 2025-01-01

STRIDE试验纳入792例有症状外周动脉疾病合并2型糖尿病患者,按糖尿病病程、BMI、HbA1c及降糖药使用分层。每周一次皮下司美格鲁肽1.0 mg在52周时显著改善最大步行距离,且各亚组间交互作用均无统计学意义,安全性与总体一致。

要点

  • 司美格鲁肽1.0 mg每周一次在52周时改善最大步行距离,各糖尿病特征亚组获益一致。
  • 最大步行距离改善与BMI下降仅弱相关,在无肥胖及HbA1c控制良好者中仍可见获益。
  • 疼痛无步行距离在各亚组间交互作用P>0.1,安全性与总体人群一致。

核心结论

  • 司美格鲁肽改善外周动脉疾病合并2型糖尿病患者的步行功能,包括无肥胖及HbA1c控制良好者,获益在各BMI和HbA1c类别间一致,支持其疗效不依赖体重或血糖变化。

研究设计与样本

  • STRIDE为随机、安慰剂对照、双盲试验(NCT04560998),纳入792例有症状外周动脉疾病合并2型糖尿病患者。
  • 主要终点为最大步行距离相对基线的比值(ETR),关键次要终点为疼痛无步行距离,均于52周时用恒定负荷跑台测量。
  • 按糖尿病病程、BMI、HbA1c及降糖药使用进行亚组分析,采用重复测量混合模型,纳入治疗、地区、亚组为固定因素,基线值为协变量,并含治疗-by-亚组交互作用。

主要发现

  • 792例参与者中位糖尿病病程12.2年、HbA1c 7.1%、BMI 28.7 kg/m2,35.1%使用钠-葡萄糖共转运蛋白2抑制剂,31.7%使用胰岛素。
  • 司美格鲁肽改善最大步行距离不因糖尿病病程而异:<10年 vs ≥10年的ETR为1.15 vs 1.13,P=0.80。
  • 司美格鲁肽改善最大步行距离不因BMI而异:<30 vs ≥30 kg/m2的ETR为1.12 vs 1.16,P=0.58。
  • 司美格鲁肽改善最大步行距离不因HbA1c而异:<7%和≥7%的ETR均为1.13,P=0.99,用药亚组同样一致。
  • 司美格鲁肽在各亚组均改善疼痛无步行距离(所有交互作用P>0.1);BMI下降与最大步行距离改善弱相关,且在基线BMI较高的对照者中更明显。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic peripheral artery disease (PAD) and type 2 diabetes. Whether these benefits are consistent across diabetes-related characteristics remains unclear. RESEARCH DESIGN AND METHODS: The primary outcome was the ratio to baseline (ETR) in maximum walking distance (MWD), with pain-free walking distance (PFWD) as a key secondary end point. Both were measured at 52 weeks using a constant load treadmill. Subgroup analyses were performed by diabetes duration, BMI, HbA1c, and diabetes medications. A mixed model for repeated measurements was used, incorporating treatment, region, and subgroup as fixed factors, and baseline value as covariate, along with the treatment-by-subgroup interaction. RESULTS: Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin. Semaglutide significantly improved MWD regardless of diabetes duration (ETR of 1.15 vs. 1.13 for <10 vs. ≥10 years, P = 0.80), BMI (1.12 vs. 1.16 for <30 vs. ≥30 kg/m2, P = 0.58), HbA1c (1.13 for <7% and ≥7%, P = 0.99), or medication use. Semaglutide also improved PFWD across subgroups (P > 0.1 for all interactions). BMI reduction correlated weakly with MWD improvements and was more pronounced in the control individuals with higher baseline BMI. Safety outcomes were consistent across subgroups. CONCLUSIONS: Semaglutide improved walking function in people with PAD and type 2 diabetes, including individuals without obesity and those with well-controlled HbA1c. Benefits were consistent across BMI and HbA1c categories, supporting effectiveness beyond weight or glycemic changes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rasouli N, Guder Arslan E, Catarig AM, et al. Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. Diabetes Care. 2025. PMID: 40543068. doi:10.2337/dc25-1082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。